Systemic immune dysfunction in pancreatic cancer patients.

Area of Science:

• Immunology
• Oncology

Background:

• Pancreatic cancer (PC) is associated with complex immune alterations.
• Understanding the immune status in PC patients is crucial for therapeutic strategies.

Purpose of the Study:

• To investigate the immune status of pancreatic cancer patients compared to healthy controls.
• To characterize peripheral blood lymphocyte (PBL) populations and their responses.
• To analyze serum cytokine levels in PC patients.

Main Methods:

• Flow cytometry was used to analyze PBL subsets (CD4+, CD8+, CD19+, CD56+).
• Blastogenic response of PBL was assessed after stimulation with mitogens (ConA, PHA, PWM) and anti-CD3 antibodies.
• Serum levels of various cytokines (TNF-alpha, IL-1beta, IL-2, IL-10, IL-12, IL-18, IL-1RA, sIL-2R, TGF-beta) were measured using ELISA.

Main Results:

• No significant differences in peripheral immunocyte distribution were observed between PC patients and healthy controls.
• PC patients showed a significantly decreased blastogenic response of PBL to PHA and anti-CD3 stimulation.
• Elevated serum levels of TNF-alpha, TGF-beta1, IL-10, IL-2R, IL-1beta, and IL-1RA were found in PC patients, along with reduced IL-2 levels.

Conclusions:

• Pancreatic cancer is characterized by systemic immune dysfunction.
• A shift towards a T helper cell type 2 cytokine profile and elevated levels of T cell suppressive substances were observed.
• Reduced PBL blastogenic response to PHA and anti-CD3 indicates impaired cellular immunity in PC.